CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07339176
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:38.439704+00:00
Published At: 2026-01-14T00:00:00+00:00
Record Updated At: 2026-01-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Neoplasms, Solid Tumor", "Breast Neoplasms, Triple-Negative", "Squamous Cell Carcinoma of Skin", "Melanoma", "Head and Neck Neoplasms", "Carcinoma, Squamous Cell", "Carcinoma, Non-Small-Cell Lung"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-14"
protocolSection.identificationModule.nctId: "NCT07339176"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.